Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C17H24O10 |
Molecular Weight | 388.3665 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 9 / 9 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12[C@@H](C)CC(=O)[C@]1([H])C(=CO[C@H]2O[C@]3([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C(=O)OC
InChI
InChIKey=HLXRWTJXGMHOFN-XJSNKYLASA-N
InChI=1S/C17H24O10/c1-6-3-8(19)11-7(15(23)24-2)5-25-16(10(6)11)27-17-14(22)13(21)12(20)9(4-18)26-17/h5-6,9-14,16-18,20-22H,3-4H2,1-2H3/t6-,9+,10+,11-,12+,13-,14+,16-,17-/m0/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/26871971Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/19904996
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26871971
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/19904996
Verbenalin is an iridoid glycoside, and an alkaloid as well, found in Verbena officinalis. Verbenalin has demonstrated cardioprotection against experimental myocardial ischemic injury. It attenuated hypoxia-induced cytotoxicity significantly in H9c2 cells in a concentration-dependent manner. Treatment of H9c2 cells with Verbenalin blocked the reduction of expression of phospho-CREB and phospho-Akt in a hypoxic condition. Verbenalin can protect myocardial function in rats during myocardial I/R injury, suggesting the therapeutic potential of Verbenalin against myocardial I/R injury. Verbenalin also exhibited significant anti-HCV entry and anti-infectivity activities.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL379 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19904996 |
|||
Target ID: Hypoxia-induced cytotoxicity, H9c2 cells Sources: https://www.ncbi.nlm.nih.gov/pubmed/26871971 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26871971
Rats: Treatment of rats with Verbenalin (30 mg/kg, iv) protected them from myocardial I/R injury
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19904996
Verbenalin gave 21.9% inhibition against HCVpp infection at a concentration of 20 ug/mL. Inhibition activity against HCVpp infection was further improved to 43.4%, respectively, after 4h enzyme incubation process.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
548-37-8
Created by
admin on Sat Dec 16 08:50:55 UTC 2023 , Edited by admin on Sat Dec 16 08:50:55 UTC 2023
|
PRIMARY | |||
|
m11423
Created by
admin on Sat Dec 16 08:50:55 UTC 2023 , Edited by admin on Sat Dec 16 08:50:55 UTC 2023
|
PRIMARY | Merck Index | ||
|
73467
Created by
admin on Sat Dec 16 08:50:55 UTC 2023 , Edited by admin on Sat Dec 16 08:50:55 UTC 2023
|
PRIMARY | |||
|
DTXSID50970143
Created by
admin on Sat Dec 16 08:50:55 UTC 2023 , Edited by admin on Sat Dec 16 08:50:55 UTC 2023
|
PRIMARY | |||
|
71B68181Z6
Created by
admin on Sat Dec 16 08:50:55 UTC 2023 , Edited by admin on Sat Dec 16 08:50:55 UTC 2023
|
PRIMARY | |||
|
118055
Created by
admin on Sat Dec 16 08:50:55 UTC 2023 , Edited by admin on Sat Dec 16 08:50:55 UTC 2023
|
PRIMARY | |||
|
Verbenalin
Created by
admin on Sat Dec 16 08:50:55 UTC 2023 , Edited by admin on Sat Dec 16 08:50:55 UTC 2023
|
PRIMARY |
SUBSTANCE RECORD